155 related articles for article (PubMed ID: 15968687)
1. Clinical management of osteoporosis in women with a history of breast carcinoma.
Van Poznak C; Sauter NP
Cancer; 2005 Aug; 104(3):443-56. PubMed ID: 15968687
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis.
Camacho PM; Dayal AS; Diaz JL; Nabhan FA; Agarwal M; Norton JG; Robinson PA; Albain KS
J Clin Oncol; 2008 Nov; 26(33):5380-5. PubMed ID: 18955450
[TBL] [Abstract][Full Text] [Related]
3. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
4. Osteodensitometry in healthy postmenopausal women.
Prescrire Int; 2008 Apr; 17(94):68-72. PubMed ID: 18536138
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology, etiology, and diagnosis of osteoporosis.
Lane NE
Am J Obstet Gynecol; 2006 Feb; 194(2 Suppl):S3-11. PubMed ID: 16448873
[TBL] [Abstract][Full Text] [Related]
6. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
[TBL] [Abstract][Full Text] [Related]
7. Evaluating bone health in women with oestrogen receptor positive breast cancer (ERBC) starting aromatase inhibitors.
Clunie GP; Clark A; Mortimer CJ; Stephenson S; Aitken J; Smith C; Sherwin E; Archer TJ
Eur J Surg Oncol; 2009 May; 35(5):475-80. PubMed ID: 18950981
[TBL] [Abstract][Full Text] [Related]
8. Prevention and treatment of postmenopausal osteoporosis.
Lewiecki EM
Obstet Gynecol Clin North Am; 2008 Jun; 35(2):301-15, ix. PubMed ID: 18486843
[TBL] [Abstract][Full Text] [Related]
9. Osteoporosis prevention and treatment: its relevance to breast cancer patients.
Hodsman AB
Can J Oncol; 1995 Dec; 5 Suppl 1():28-32. PubMed ID: 8853521
[TBL] [Abstract][Full Text] [Related]
10. The causes and treatment of bone loss associated with carcinoma of the breast.
Lester J; Dodwell D; McCloskey E; Coleman R
Cancer Treat Rev; 2005 Apr; 31(2):115-42. PubMed ID: 15847981
[TBL] [Abstract][Full Text] [Related]
11. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
[TBL] [Abstract][Full Text] [Related]
12. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society.
North American Menopause Society
Menopause; 2006; 13(3):340-67; quiz 368-9. PubMed ID: 16735931
[TBL] [Abstract][Full Text] [Related]
13. Update on identifying and managing osteoporosis in women with breast cancer.
Yamamoto DS; Viale PH
Clin J Oncol Nurs; 2009 Oct; 13(5):E18-29. PubMed ID: 19793700
[TBL] [Abstract][Full Text] [Related]
14. Screening, prevention, detection, and treatment of cancer therapy-induced bone loss in patients with breast cancer.
Limburg CE
Oncol Nurs Forum; 2007 Jan; 34(1):55-63. PubMed ID: 17562633
[TBL] [Abstract][Full Text] [Related]
15. Adverse bone effects during pharmacological breast cancer therapy.
Bjarnason NH; Hitz M; Jorgensen NR; Vestergaard P
Acta Oncol; 2008; 47(4):747-54. PubMed ID: 18465344
[TBL] [Abstract][Full Text] [Related]
16. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis.
Hadji P
Crit Rev Oncol Hematol; 2009 Jan; 69(1):73-82. PubMed ID: 18757208
[TBL] [Abstract][Full Text] [Related]
17. The adherence to practice guidelines in the assessment of bone health in women with chemotherapy-induced menopause.
Tham YL; Sexton K; Weiss HL; Elledge RM; Friedman LC; Kramer RM
J Support Oncol; 2006 Jun; 4(6):295-8, 304. PubMed ID: 16805332
[TBL] [Abstract][Full Text] [Related]
18. Aromatase inhibitors and bone health.
Bundred NJ
Curr Opin Obstet Gynecol; 2009 Feb; 21(1):60-7. PubMed ID: 19125005
[TBL] [Abstract][Full Text] [Related]
19. Peripheral and central measurements of bone mineral density are equally strongly associated with clinical risk factors for osteoporosis.
Patel R; Blake GM; Fogelman I
Calcif Tissue Int; 2007 Feb; 80(2):89-96. PubMed ID: 17308990
[TBL] [Abstract][Full Text] [Related]
20. Cancer treatment-induced bone loss in breast and prostate cancer.
Saad F; Adachi JD; Brown JP; Canning LA; Gelmon KA; Josse RG; Pritchard KI
J Clin Oncol; 2008 Nov; 26(33):5465-76. PubMed ID: 18955443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
